California Pacific Medical Center
- Type
- Teaching hospital
- Where
- San Francisco, CA
- Medicare CCN
- 050047
- Received
- $913,618 in 113 records, 2023 ($7,357 general, $906,261 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: CALIFORNIA PACIFIC MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: CALIFORNIA PACIFIC MEDICAL CENTER Fuzzy (name and state)
- Nonprofit: CALIFORNIA PACIFIC MEDICAL CENTER Fuzzy (name and state)
- Patent assignee: CALIFORNIA PACIFIC MEDICAL CENTER Fuzzy (name and state)
- Trademark owner: CALIFORNIA PACIFIC MEDICAL CENTER Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2023 | General payment | 6 | $7,357 |
| 2023 | Research payment | 107 | $906,261 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Merck Sharp & Dohme LLC | 12 | $527,668 | 2023 |
| Genentech, Inc. | 15 | $216,050 | 2023 |
| PTC Therapeutics, Inc. | 6 | $40,687 | 2023 |
| Amylyx Pharmaceuticals, Inc. | 1 | $28,798 | 2023 |
| ModernaTX, Inc. | 6 | $28,100 | 2023 |
| Boston Scientific Corporation | 16 | $25,590 | 2023 |
| Medtronic, Inc. | 8 | $17,074 | 2023 |
| Regeneron Pharmaceuticals, Inc. | 8 | $13,466 | 2023 |
| CSL Behring | 33 | $7,824 | 2023 |
| Jenavalve Technology, Inc. | 1 | $4,986 | 2023 |
| Sterilmed, Inc. | 3 | $1,463 | 2023 |
| Medline Industries LP | 2 | $907 | 2023 |
| F. Hoffmann-La Roche AG | 1 | $500 | 2023 |
| Amgen Inc. | 1 | $500 | 2023 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 107 | $906,261 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 4 | $6,449 |
| Debt forgiveness | 2 | $907 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2023-12-31 | Merck Sharp & Dohme LLC | $263,518 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase II study of olaparib in combination with pembrolizumab in patients with advanced melanoma with homologous recombin | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $135,048 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK 7684A Vibostolimab with | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $55,638 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $23,372 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase Ib,II Trial of Pembrolizumab MK-3475 Combination Therapies in Metastatic Castration-Resistant Prostate Cancer mCRP | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $19,030 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety andEfficacy of Pembrolizumab MK-3475 and Lenvatini | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $2,887 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection | 2023 |
| 2023-12-31 | Medline Industries LP | $659 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-12-31 | Merck Sharp & Dohme LLC | $543 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety andEfficacy of Pembrolizumab MK-3475 and Lenvatini | 2023 |
| 2023-12-31 | Medline Industries LP | $248 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-12-31 | Merck Sharp & Dohme LLC | $41 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician s C | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $4 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A phase III study of Lenalidomide and low-dose Dexamethasone with or without Pembrolizumab MK3475 in newly diagnosed and | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refracto | 2023 |
| 2023-12-12 | F. Hoffmann-La Roche AG | $500 | Research payment | Cash or cash equivalent | Cotellic Drug, BioOncology | Ph 1b study of cobimetinib and PARP inhibitor with or without atezolizumab in PSOC | 2023 |
| 2023-12-11 | Medtronic, Inc. | $10,500 | Research payment | Cash or cash equivalent | ONYX 18 Device, Liquid Embolics | EMBOLISE | 2023 |
| 2023-12-08 | CSL Behring | $243 | Research payment | Cash or cash equivalent | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 | |
| 2023-12-05 | PTC Therapeutics, Inc. | $13,733 | Research payment | Cash or cash equivalent | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK | 2023 | |
| 2023-12-05 | PTC Therapeutics, Inc. | $5,380 | Research payment | Cash or cash equivalent | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK | 2023 | |
| 2023-11-20 | Boston Scientific Corporation | $6,396 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, WATCHMAN IC | OPTION | 2023 |
| 2023-11-20 | Boston Scientific Corporation | $500 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, WATCHMAN IC | OPTION | 2023 |
| 2023-11-20 | CSL Behring | $36 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 | |
| 2023-11-17 | CSL Behring | $5,989 | Research payment | Cash or cash equivalent | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 | |
| 2023-11-17 | CSL Behring | $36 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 | |
| 2023-11-17 | CSL Behring | $18 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 | |
| 2023-11-08 | ModernaTX, Inc. | $14,908 | Research payment | Cash or cash equivalent | A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Ve | 2023 | |
| 2023-11-08 | ModernaTX, Inc. | $4,009 | Research payment | Cash or cash equivalent | A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Ve | 2023 | |
| 2023-11-02 | Genentech, Inc. | $750 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | 2023 |
| 2023-10-19 | CSL Behring | $108 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 | |
| 2023-10-19 | CSL Behring | $36 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 | |
| 2023-10-19 | CSL Behring | $36 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 | |
| 2023-10-19 | CSL Behring | $36 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 | |
| 2023-10-19 | CSL Behring | $36 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 | |
| 2023-10-19 | CSL Behring | $36 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 | |
| 2023-10-19 | CSL Behring | $18 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 | |
| 2023-10-04 | Genentech, Inc. | $21,655 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | 2023 |
| 2023-09-25 | Merck Sharp & Dohme LLC | $20,446 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety andEfficacy of Pembrolizumab MK-3475 and Lenvatini | 2023 |
| 2023-09-19 | Boston Scientific Corporation | $1,374 | Research payment | Cash or cash equivalent | Farapulse Device, Structural Heart | ADVENT | 2023 |
| 2023-09-18 | Boston Scientific Corporation | $1,248 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, WATCHMAN IC | OPTION | 2023 |
| 2023-08-21 | Boston Scientific Corporation | $274 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, WATCHMAN IC | OPTION | 2023 |
| 2023-08-17 | Genentech, Inc. | $1,550 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | 2023 |
| 2023-08-16 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2023 |
| 2023-08-14 | CSL Behring | $90 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 | |
| 2023-08-14 | CSL Behring | $54 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 | |
| 2023-08-11 | ModernaTX, Inc. | $5,346 | Research payment | Cash or cash equivalent | A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v | 2023 | |
| 2023-08-04 | Genentech, Inc. | $28,068 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | 2023 |
| 2023-08-03 | PTC Therapeutics, Inc. | $18,104 | Research payment | Cash or cash equivalent | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK | 2023 | |
| 2023-08-03 | Jenavalve Technology, Inc. | $4,986 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (3 payments) | Cash or cash equivalent | JenaValve Pericardial TAVR System Device, Cardiology | 2023 | |
| 2023-07-26 | Boston Scientific Corporation | $3,878 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, WATCHMAN IC | OPTION | 2023 |
| 2023-07-04 | PTC Therapeutics, Inc. | $1,469 | Research payment | Cash or cash equivalent | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK | 2023 | |
| 2023-06-22 | Genentech, Inc. | $71,738 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | 2023 |
| 2023-06-20 | Regeneron Pharmaceuticals, Inc. | $1,268 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2023 |
| 2023-06-14 | CSL Behring | $36 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 | |
| 2023-06-14 | CSL Behring | $36 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 | |
| 2023-06-14 | CSL Behring | $36 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 | |
| 2023-06-14 | CSL Behring | $36 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 | |
| 2023-06-07 | ModernaTX, Inc. | $1,336 | Research payment | Cash or cash equivalent | A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v | 2023 | |
| 2023-06-01 | Boston Scientific Corporation | $1,104 | Research payment | Cash or cash equivalent | Farapulse Device, Structural Heart | ADVENT | 2023 |
| 2023-05-30 | Regeneron Pharmaceuticals, Inc. | $1,119 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2023 |
| 2023-05-25 | Genentech, Inc. | $6,898 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | 2023 |
| 2023-05-23 | Genentech, Inc. | $16,620 | Research payment | Cash or cash equivalent | Phase Ib belvarafenib alone and in combo with cobi or cobi atezo in NRAS m adv melanoma patients | 2023 | |
| 2023-05-22 | Boston Scientific Corporation | $1,221 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, WATCHMAN IC | OPTION | 2023 |
| 2023-05-01 | Boston Scientific Corporation | $2,208 | Research payment | Cash or cash equivalent | Farapulse Device, Structural Heart | ADVENT | 2023 |
| 2023-04-28 | Amgen Inc. | $500 | Research payment | Cash or cash equivalent | IMLYGIC Biological, Oncology | P1b2 talimogene laherparepvec + Yervoy combo melanoma | 2023 |
| 2023-04-26 | Regeneron Pharmaceuticals, Inc. | $2,330 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2023 |
| 2023-04-20 | Merck Sharp & Dohme LLC | $7,136 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection | 2023 |
| 2023-04-20 | Genentech, Inc. | $1,350 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | 2023 |
| 2023-04-20 | Genentech, Inc. | $750 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | 2023 |
| 2023-04-04 | PTC Therapeutics, Inc. | $1,000 | Research payment | Cash or cash equivalent | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK | 2023 | |
| 2023-04-01 | Boston Scientific Corporation | $1,104 | Research payment | Cash or cash equivalent | Farapulse Device, Structural Heart | ADVENT | 2023 |
| 2023-03-31 | Sterilmed, Inc. | $424 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-03-29 | CSL Behring | $156 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 | |
| 2023-03-29 | CSL Behring | $65 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 | |
| 2023-03-29 | CSL Behring | $54 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 | |
| 2023-03-29 | CSL Behring | $54 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 | |
| 2023-03-29 | CSL Behring | $54 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 | |
| 2023-03-29 | CSL Behring | $54 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 | |
| 2023-03-29 | CSL Behring | $54 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 | |
| 2023-03-29 | CSL Behring | $54 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 | |
| 2023-03-29 | CSL Behring | $54 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 | |
| 2023-03-29 | CSL Behring | $54 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 | |
| 2023-03-29 | CSL Behring | $54 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 | |
| 2023-03-29 | CSL Behring | $54 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 | |
| 2023-03-29 | CSL Behring | $54 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 | |
| 2023-03-29 | CSL Behring | $54 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 | |
| 2023-03-29 | CSL Behring | $39 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2023 | |
| 2023-03-23 | Genentech, Inc. | $24,659 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | 2023 |
| 2023-03-22 | ModernaTX, Inc. | $500 | Research payment | Cash or cash equivalent | A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v | 2023 | |
| 2023-03-16 | Amylyx Pharmaceuticals, Inc. | $28,798 | Research payment | Cash or cash equivalent | RELYVRIO Drug, NEUROLOGY | Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment (Phoenix) | 2023 |
| 2023-03-08 | Regeneron Pharmaceuticals, Inc. | $2,388 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2023 |
| 2023-03-03 | Genentech, Inc. | $12,505 | Research payment | Cash or cash equivalent | A study of balovaptan in acute ischemic stroke | 2023 | |
| 2023-02-28 | Sterilmed, Inc. | $287 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-02-23 | Genentech, Inc. | $1,000 | Research payment | Cash or cash equivalent | A study of balovaptan in acute ischemic stroke | 2023 | |
| 2023-02-22 | Regeneron Pharmaceuticals, Inc. | $1,119 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2023 |
| 2023-02-21 | Boston Scientific Corporation | $1,698 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, WATCHMAN IC | OPTION | 2023 |
| 2023-02-13 | Genentech, Inc. | $100 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | 2023 |
| 2023-02-09 | Regeneron Pharmaceuticals, Inc. | $1,119 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2023 |
| 2023-02-03 | PTC Therapeutics, Inc. | $1,000 | Research payment | Cash or cash equivalent | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK | 2023 | |
| 2023-02-01 | Boston Scientific Corporation | $1,104 | Research payment | Cash or cash equivalent | Farapulse Device, Structural Heart | ADVENT | 2023 |
| 2023-02-01 | Boston Scientific Corporation | $1,000 | Research payment | Cash or cash equivalent | Farapulse Device, Structural Heart | ADVENT | 2023 |
| 2023-02-01 | Boston Scientific Corporation | $500 | Research payment | Cash or cash equivalent | Farapulse Device, Structural Heart | ADVENT | 2023 |
| 2023-01-31 | Sterilmed, Inc. | $751 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-01-27 | Medtronic, Inc. | $1,000 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2023 |
| 2023-01-25 | Genentech, Inc. | $3,500 | Research payment | Cash or cash equivalent | A study of balovaptan in acute ischemic stroke | 2023 | |
| 2023-01-23 | Medtronic, Inc. | $1,000 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | Optimize Pro | 2023 |
| 2023-01-20 | Regeneron Pharmaceuticals, Inc. | $2,388 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2023 |
| 2023-01-19 | Genentech, Inc. | $24,907 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS | 2023 |
| 2023-01-18 | ModernaTX, Inc. | $2,000 | Research payment | Cash or cash equivalent | A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab v | 2023 | |
| 2023-01-18 | Medtronic, Inc. | $500 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2023 |
| 2023-01-17 | Boston Scientific Corporation | $1,221 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, WATCHMAN IC | OPTION | 2023 |
| 2023-01-17 | Medtronic, Inc. | $74 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | Optimize Pro | 2023 |
| 2023-01-06 | Regeneron Pharmaceuticals, Inc. | $1,732 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY A | 2023 |
| 2023-01-03 | Medtronic, Inc. | $2,000 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2023 |
| 2023-01-03 | Medtronic, Inc. | $1,500 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | SMART Trial | 2023 |
| 2023-01-01 | Boston Scientific Corporation | $756 | Research payment | Cash or cash equivalent | Farapulse Device, Structural Heart | ADVENT | 2023 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In San Francisco, CA, county San Francisco County, CA, state California; placed by its city name.
| Measure | Place (city or town) San Francisco, CA | County San Francisco County, CA | State California |
|---|---|---|---|
| Population B01003 | 830,235 | 830,235 | 39,287,377 |
| Population, 2020 census P1 | 873,965 | 873,965 | 39,538,223 |
| Median age B01002 | 40.0 | 40.0 | 37.9 |
| Under 18 B01001 | 13.7% | 13.7% | 22.0% |
| 65 and over B01001 | 17.6% | 17.6% | 15.7% |
| Households B11001 | 363,970 | 363,970 | 13,548,091 |
| Foreign born B05002 | 34.0% | 34.0% | 27.0% |
| Median household income B19013 | $140,970 | $140,970 | $99,122 |
| Median family income B19113 | $171,141 | $171,141 | $113,346 |
| Per capita income B19301 | $92,289 | $92,289 | $49,513 |
| Poverty rate B17001 | 11.2% | 11.2% | 12.0% |
| Unemployment rate B23025 | 6.1% | 6.1% | 6.6% |
| Civilian labor force B23025 | 507,262 | 507,262 | 20,068,466 |
| Mean commute (minutes) B08013 | 30.4 | 30.4 | 28.7 |
| Bachelor's degree or higher B15003 | 60.3% | 60.3% | 37.1% |
| Housing units B25001 | 414,602 | 414,602 | 14,644,735 |
| Owner-occupied B25003 | 38.2% | 38.2% | 55.9% |
| Renters B25003 | 61.8% | 61.8% | 44.1% |
| Median home value B25077 | $1,394,500 | $1,394,500 | $734,700 |
| Median gross rent B25064 | $2,476 | $2,476 | $2,036 |
| White, not Hispanic B03002 | 36.8% | 36.8% | 33.8% |
| Black B03002 | 4.7% | 4.7% | 5.2% |
| Hispanic or Latino B03002 | 16.2% | 16.2% | 40.2% |
| Asian B03002 | 34.9% | 34.9% | 15.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in San Francisco, CA.
Comments